Rare Disease Report
Patients & Caregivers


October is Liver Cancer Awareness month, and the Fibrolamellar Cancer Foundation is making sure the world's fifth most common cancer type is properly recognized.
This morning, Astellas announced that it was granted Fast Track designation for the development of gilternitinb in adult patients with AML.
Boston Biomedical has announced that the FDA has granted orphan drug designation to DSP-7888, a vaccine for the treatment of patients with brain cancer.
FDA granted Breakthrough Therapy Designation for Tagrisso (osimertinib) as a first-line treatment for metastatic EGFR+  NSCLC.
Trovagene, Inc. was granted Orphan Drug Designation from the U.S. Food and Drug Administration for its acute myeloid leukemia drug PCM-075.
Data from the GALLIUM Study that obinutuzumab-based immunochemotherapy and maintenance therapy is better for follicular lymphoma than rituximab-based therapy.
Patients with this rare lung cancer can now opt to orally ingest a 180 mg tablet
Clinical advancements in screening tests, surgical procedures, chemotherapy, etc are also helping to control this rare disease.
Pfizer announced plans for SpringWorks Therapeutics, which will be focused on just 4 experimental drugs, 3 of which are for rare diseases.
The European Commission (EC) has approved the first-ever immunotherapy for the rare and aggressive skin cancer metastatic merkel cell carcinoma (mMCC).
Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.